Group 1 - The article emphasizes the strategic significance of innovative drugs and suggests improving capital market support mechanisms and strengthening intellectual property protection [1] - The biopharmaceutical sector has experienced a significant recent pullback, primarily due to substantial gains in the innovative drug sector since the beginning of the year, leading some investors to take profits [1] - The National Medical Products Administration (NMPA) has proposed to shorten the clinical trial review and approval process for innovative drugs to 30 working days, further encouraging innovative drug development [1] Group 2 - The adjustment of the medical insurance catalog is about to begin, with the commercial health insurance innovative drug catalog being included in the adjustment system, necessitating attention to subsequent selection principles and support policies [1] - The NMPA has deployed measures to support the innovative development of high-end medical devices, introducing initiatives for areas such as medical robots, high-end imaging equipment, and AI medical devices, presenting new opportunities for high-end equipment [1] - The current price-to-earnings (PE) ratio for the biopharmaceutical sector is 27.21 times, which is at the historical median level, while the PE ratio for the bioproducts sub-sector reaches 32.85 times [1]